Sponsors Want Answers On Consequences Of Missing US FDA Trial Diversity Goals
Executive Summary
No negative actions have been taken in the US FDA’s oncology review divisions, but vague diversity guidance continues to raise concerns.
You may also be interested in...
Payers, Medical Journals Could Help Push For Clinical Trial Diversity, Cavazzoni Says
The director of the US FDA’s Center for Drug Evaluation and Research acknowledged that the FDA cannot improve trial diversity alone.
China Rhetoric Could Be Key To US FDA IT System Upgrade
FDA Commissioner Robert Califf says mentioning China helps increase congressional support.
Racial And Ethnic Diversity In Clinical Trials: A Social And Scientific Imperative
From new FDA guidance and community engagement efforts to the challenges of precision medicine and decentralization, In Vivo spoke with industry experts about racial and ethnic diversity in the context of clinical trials.